A Life Sciences Company Operating Under a Consent Decree | Deloitte US has been added to your bookmarks.
Operating under a Consent Decree
Managing a Life Sciences company through a major regulatory action
Through planning and commitment, your company can mitigate the near-term disruptions caused by a Consent Decree and eventually emerge as a stronger, more compliant, and quality conscious company, well-positioned for long-term success.
Tarnished reputations, lost sales, massive fines & remediation expenses, cultural change and hostile working environments, diminished morale, legal disputes, employee retention, and product shortages are common challenges faced by Life Sciences companies operating under Consent Decrees (CD). There is no aspect of the business that is unaffected, and the impacts can extend to customers and patients as well. It takes a broad-based effort to effectively address the concerns of regulatory agencies while simultaneously preparing the company to manage its current business as well as their mid- and long-term operations. The effort involved goes well beyond simply developing and executing a remediation plan and should consider the strategies and tactics to design and manage an organization that not only has to survive as the remediation efforts are underway, but also thrive in the future.